Naronapride Shows Promise for Treating Gastroparesis
A Phase 2b trial found that specific doses of naronapride significantly improved gastroparesis symptoms in adults.
Updated on Oct. 30, 2026 in Diabetes
Live Poll
Is pharmaceutical research for chronic digestive conditions significantly improving quality of life for patients?
Results presented in October 2026 showed that 20 mg and 40 mg doses of naronapride outperformed placebos in managing idiopathic or diabetic gastroparesis. Patients receiving these dosages also reported improved quality of life over the 12-week study period.
Why it matters
Naronapride is designed to function locally in the gut to boost motility and reduce nausea, offering a potential new treatment pathway for patients. The study suggests the drug can address core symptoms without negatively impacting glycemic control or showing cardiac safety risks.
The multicenter trial involved 328 adult participants with a mean age of 51.1 years, 79.9% of whom were women. While the 20 mg and 40 mg doses showed significant symptom improvement, the 10 mg dose did not differ significantly from the placebo.
The players
Naronapride
This is a dual-action prokinetic drug designed to treat gastroparesis by acting locally within the gut.
The details
Naronapride functions as a dual-action prokinetic that stimulates serotonin receptors to increase gut motility while blocking dopamine receptors to alleviate nausea. Participants with diabetic etiology comprised 27.4% of the total study group.
Timeline
The clinical trial treatment lasted for a duration of 12 weeks.
Results were presented in October 2026 at United European Gastroenterology Week.
Health Landscape
This drug represents an evolution in the development of prokinetic agents for gastrointestinal motility disorders by targeting specific receptor pathways to manage symptoms locally. The study marks a potential advancement by demonstrating efficacy in both idiopathic and diabetic cases.
Patients suffering from gastroparesis may see expanded treatment options in the future as researchers continue to refine effective dosages. The lack of cardiac or prolactin-related safety signals suggests a potentially favorable profile for future clinical use.
The takeaway
Naronapride shows significant potential in treating gastroparesis symptoms by balancing motility improvements with nausea reduction. Patients should monitor future clinical announcements as this drug moves toward potential regulatory review.
Further reading
Learn more about the latest innovations in managing digestive complications related to Diabetes.
Source note: This article includes information reported by Medscape.
Live Poll
Is pharmaceutical research for chronic digestive conditions significantly improving quality of life for patients?
